Synopsis: Intellectual Property rights are key assets in growing and defending market share. Differentiation through an intellectual property can help secure new customers and build recognized brand value. Moreover, as legally protected commercial assets, IP provides an arsenal of ways to assert and defend against competition.
Join us to hear from panelists representing healthcare and life sciences companies, from ventures to global multinationals. Learn from their insights on aligning IP strategy with business strategy to compete and win.
Ainslie Little, Senior Director, Head of Intellectual Property at BlueRock Therapeutics
Ainslie Little has focused on patent strategy and protection of stem cell technologies for almost a decade. At BlueRock Therapeutics, Ainslie is responsible for developing and executing intellectual property strategies, building and managing global patent and trademark portfolios, conducting due diligence to support business objectives, and developing and implementing IP policies and education programs. Before joining BlueRock Therapeutics, Ainslie practiced at leading law firms in Canada and the United States where she focused on drafting and prosecuting patent applications and advising universities, SMEs, and multinational pharmaceutical companies on patentability, validity, infringement and freedom-to-operate matters. Ainslie is a registered patent agent in the United States and Canada. She holds a B.Sc. from the University of Guelph and a Ph.D. in microbiology from the University of Wisconsin-Madison.
Wendy Naimark, PhD, VP of R&D, Ripple Therapeutics
Dr. Naimark is the VP of R&D at Ripple Therapeutics, a recently announced spin out from Interface Biologics, founded on the discovery that drugs can be engineered into controlled release Pharmaceuticals and Device coasting without the use of polymers. Dr. Naimark has been leading teams in the development of local drug delivery products for over 18 years; prior to joining Ripple/IBI, Dr.Naimark led the Clinical Program for the development of a drug-eluting, self-expanding, biodegradable scaffold at 480 Biomedical. Dr. Naimark began her industry career at Boston Scientific in the Corporate R&D group, which developed the TAXUS® Drug Eluting Stent. At Boston Scientific her work spanned developing combination products to deliver angiogenic biological agents to leading Regulatory Submission Strategies for approval of Class III combination products. Dr Naimark received her PhD in Biomaterials from the University of Toronto and began developing her career interest in local drug delivery at Caltech during her post-doctoral fellowship. Dr. Naimark is an inventor of 33 patents in the local drug delivery field.
Robert Shapiro, Global Director, Portfolio Management, Apotex Inc.
With a wall full of diplomas and awards, Robert’s background is the right fit for a senior leader at a generic pharmaceutical company. Robert is a chemist, a US and Canadian licensed lawyer with over 10 years of experience in patent law and he completed the executive MBA program at Rotman in 2017 as part of his career evolution.
Robert is the Global Director of Portfolio Management at Apotex, where he is responsible for managing a portfolio of more than 500 products in over 100 countries. Robert works with cross-functional teams to identify and select the right products, monitor timelines, support the launch, and oversee product lifecycle management. Robert has led a number of portfolio initiatives to optimize Apotex’s portfolio.
Outside of work, Robert is an avid cyclist, loves to camp in the wilderness, a big sports fan and his favourite job is being the father to 3 young boys.
Dr. Beau Standish, Chief Executive Officer, 7D Surgical
Dr. Standish has 15+ years of extensive experience in the commercialization of medical imaging technologies and is a co-founder and the Chief Executive Officer of 7D Surgical. He provides executive and financial leadership, has recruited key team members and oversees the day-to-day operations of the organization. He has led the >$30M CAD private financing/leveraged funding opportunities for 7D Surgical in addition to the development of strategic collaborations and partnerships with the generation of over $15M CAD revenue in the last 1.5 years alone. He is the author on >50 patents and software copyrights and has defined 7D Surgical’s go-to-market corporate strategy including product development, pricing, positioning, messaging, branding and communication roll-out. Dr. Standish was previously employed at a successful high-tech parallel transceiver company, Xanoptix Inc. (USA) and was an assistant professor in the Department of Electrical and Computer Engineering at Ryerson University in Toronto Canada. He is a professional engineer and holds a PhD in Medical Biophysics from the University of Toronto, where he was a Terry Fox Scholar of the National Cancer Institute of Canada.
Paul Stewart, Managing Director of PASCO Ventures
Paul A. Stewart is Managing Director of PASCO Ventures LLC, a Denver-based independent advisory firm he founded after retiring from Eli Lilly and Company in 2012. He has deep expertise in licensing from over 25 years of executive and leadership experience and through completing global and regional transactions in the Americas, Europe, Africa and Asia. These transactions have produced over a dozen human pharmaceuticals, medical devices and animal health products that are in the market today or have been publicly disclosed while in development, plus other as-yet-undisclosed developments.
Stewart has led and served on numerous professional, academic, civic and not-for-profit boards, is a Certified Licensing Professional, is listed in “Who’s Who in America,” “Who’s Who in the World” and “Who’s Who in Medicine and Healthcare,” and is the author of “A Harvard MBA’s Advice to His Sons” (ISBN 1594539952). He also served as a distinguished lecturer for the Graduate Program of International Pharmaceutical Engineering Management (IPEM) at Peking University in Beijing, China.
Paul Stewart received a Bachelor of Science degree in agricultural business management from Purdue University and a Master of Business Administration degree from Harvard Business School.
About the Sandra Rotman Centre for Health Sector Strategy
Driving Excellence in Healthcare Management
The Sandra Rotman Centre for Health Sector Strategy is a research, education and policy centre aimed at generating insights for governments, organizations and other key stakeholders facing complex healthcare challenges.
Entrepreneurship at UofT
The U of T Entrepreneurship community is Canada's leading engine for research-based startups and a global leader in transforming ideas into products and services that create jobs and impact the world. More than 500 research-based startups have been launched from U of T, outpacing every other Canadian university and generating more than $1.5 billion (CAD) in investment in the past 10 years. In 2019, UBI Global ranked U of T Entrepreneurship in the global top 10 university-managed incubators in the world.
Questions? Rosemary Hannam, firstname.lastname@example.org, 416-946-3492